Yale professor Craig Crews says the partnershop reflects "a new paradigm" of how academics and the pharmaceutical industry can partner.

UK-based pharmaceutical company GlaxoSmithKline and US-based Yale University [the Beinecke Library is pictured] set up a drug discovery research collaboration on Tuesday last week.

The partnership is designed to develop Yale’s work on "proteolysis targeting chimeric molecules", which help the body destroy disease-causing proteins. The two institutions are looking to show these molecules can be turned into medicines.

The pair said in a statement: "GSK will then have the right to use this technology for multiple disease-causing proteins across all…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?